NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology firm, announced that CEO Kristi Jones will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 11:00 am ET. The presentation will be available via webcast on the company’s Investor Relations page, with a replay accessible for 30 days. NexImmune is pioneering a unique immunotherapy approach leveraging its AIM™ nanoparticle technology to promote targeted immune responses. Their lead candidates, NEXI-001, NEXI-002, and NEXI-003, are in Phase 1/2 trials for treating various cancers.

GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24^th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.

The webcast will be accessible on the Investor Relations page of NexImmune’s website at Events and Presentations | NexImmune, Inc. A replay of the presentation will be available at the same location for 30 days following the conference.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response.

NexImmune’s lead programs, NEXI-001, NEXI-002 and NEXI-003, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation, multiple myeloma refractory to 3 or more prior lines of therapy and HPV-related cancers, respectively. NexImmune is also developing AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

For more information, visit www.neximmune.com.

Contacts
Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
crubin@neximmune.com

FAQ

When is NexImmune's presentation at the H.C. Wainwright conference?

NexImmune's presentation is scheduled for September 12 at 11:00 am ET.

What is the AIM technology used by NexImmune?

AIM technology is a proprietary nanoparticle platform that directs T cell-mediated immune responses in cancer treatments.

What clinical trials are underway for NEXI-001, NEXI-002, and NEXI-003?

NEXI-001 targets relapsed AML, NEXI-002 focuses on multiple myeloma, and NEXI-003 is for HPV-related cancers.

Where can I watch the NexImmune presentation?

The presentation will be accessible on NexImmune's Investor Relations webpage and available to replay for 30 days.

What is NexImmune's focus in the biotechnology field?

NexImmune is focused on developing immunotherapies that utilize the body’s own T cells to generate a potent immune response.